ALKS Alkermes plc

18.41
+0.53  (+3%)
Previous Close 17.88
Open 17.94
Price To Book 2.65
Market Cap 2,891,988,914
Shares 157,130,612
Volume 967,649
Short Ratio
Av. Daily Volume 1,084,724
Stock charts supplied by TradingView

NewsSee all news

  1. Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

    DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the  presentation of new health economics and outcomes research at the 32nd Annual Psych Congress (Psych Congress), which took place Oct.

  2. Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

    DUBLIN, Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at

  3. Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

    DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Schizophrenia
Noted July 15, 2019 that NDA filing due 4Q 2019 will include Bipolar I indication
ALKS 3831 - ENLIGHTEN-2
Schizophrenia, bipolar
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
Phase 1/2 initial data to be presented fall of 2019.
ALKS 4230 ARTISTRY-1
Solid tumors
Phase 3 data released April 9, 2019 - primary endpoint met.
Aristada and Invega Sustenna
Schizophrenia
Phase 1 initiation announced February 26, 2019.
ALKS 4230 + Keytruda - ARTISTRY-2
Solid tumors
Phase 3 top-line data met primary endpoint - July 30, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -
Relapsing Remitting Multiple Sclerosis (RRMS)

Latest News

  1. Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

    DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the  presentation of new health economics and outcomes research at the 32nd Annual Psych Congress (Psych Congress), which took place Oct.

  2. Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

    DUBLIN, Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at

  3. Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

    DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of